ORPHA:370131
White platelet syndrome
Publications
20
25.8th percentile
Trials
0
Interventional, condition-specific
Researchers
71
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
White platelet syndrome (WPS) is a platelet granule disorder characterized by thrombocytopenia, increased mean platelet volumes, decreased platelet responsiveness to aggregating agents, and significant defects in platelet ultrastructural morphology leading to prolonged bleeding times and bleeding.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018269
- MeSH:C536702
- UMLS:C2931293
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
20 matched papers (8 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
20
20 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
20 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
8 in the last 10 years · high confidence · 25.8th percentile (publications denominator)
Phrase hits: 20 · MeSH hits: 2
Who's working on it?
71
Distinct author names in 20 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01White JG7 papers · 2013
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis 55455, USA. white003@umn.edu
Papers in Europe PMC - 02Key NS2 papers · 2005Papers in Europe PMC
- 03King RA2 papers · 2005Papers in Europe PMC
- 04Vercellotti GM2 papers · 2005Papers in Europe PMC
- 05Wu M2 papers · 2021
College of Animal Science and Technology, Jilin Agricultural University, Changchun, 130118, China.
Papers in Europe PMC - 06Åström M1 paper · 2021
Department of Medicine, Faculty of Medicine and Health, Örebro University, Örebro. maria.astrom@regionorebrolan.se.
Papers in Europe PMC - 07Bareš M1 paper · 2016
First Department of Neurology, St. Anne's University Hospital, Brno, Czech Republic; Medical Faculty of Masaryk University, Brno, Czech Republic; Behavioral and Social Neuroscience Research Group, CEITEC (Central European Institute of Technology), Masaryk University, Brno, Czech Republic; Department of Neurology, School of Medicine, University of Minnesota, Minneapolis, MN, USA.
Papers in Europe PMC - 08Bergemalm D1 paper · 2021
Department of Medicine, Faculty of Medicine and Health, Örebro University, Örebro.
Papers in Europe PMC - 09Bergström J1 paper · 2021
Proteomics Core Facility, University of Gothenburg, Gothenburg.
Papers in Europe PMC - 10Blair P1 paper · 2009
Department of Medicine, Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 40 · after dedupe 40 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 40 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (40)
- isrctn·ISRCTN11301892·No longer recruiting·Biological impact of an intensive 21-day spa recovery program on quality of life and cell health in Parkinson’s disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12537955·Not yet recruiting·Comparing a new combination of medicines to the usual intensive chemotherapy treatment given to participants who have been recently diagnosed with acute myeloid leukaemia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16819837·Recruiting·The use of CARBALIVE in the treatment of cholestatic liver disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN46157068·Recruiting·Identifying candidates for early respiratory failure treatment based on Interleukin-6 levels
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16011638·Recruiting·A study of a traditional Chinese herbal formula combined with standard medication for treating a specific type of rheumatoid arthritis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN37340032·Recruiting·A study of bleximenib, venetoclax and azacitidine for treatment of participants with newly diagnosed acute myeloid leukemia (cAMeLot-2)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15824224·No longer recruiting·Comparison of the effect of iguratimod and hydroxychloroquine in the treatment of primary Sjögren's syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10492452·Recruiting·Treatment of patients with Fahr's disease or syndrome with Etidronate
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16221474·Recruiting·A study of JNJ-89853413 for relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasms
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10023611·Recruiting·A study of JNJ-80948543 in combination with other CD3 T-cell engagers in participants with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-Cell NHL)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15356845·Recruiting·A CAR T study for paediatric-type diffuse high-grade gliomas including diffuse midline glioma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN57038506·Recruiting·A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of the study drug MYTX-011 in Subjects with Non-Small Cell Lung Cancer Cell Lung Cancer – KisMET-01
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN98745687·No longer recruiting·A Phase Ib/II, open-label study of amivantamab monotherapy and amivantamab in addition to other therapeutic agents in participants with head and neck squamous cell carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16253842·No longer recruiting·A study to determine the safety of higher doses of OMS906 in healthy volunteers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14477643·No longer recruiting·Mobile Application (Virtusan), a science-based habit formation educational digital tool for empowerment of healthier lifestyle, optimum nutritional habits, physical & mental health, sleep status, and quality of life. The VIRTUSAN Clinical Trial.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17828080·Recruiting·Steroid-Reducing Options for ReLapsING PMR (STERLING-PMR)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN50261938·Suspended·Study to evaluate treatment efficacy by monitoring minimal residual disease in an early breast cancer population
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN71474257·Stopped·Comparing a new combination of medicines to the normal standard of care chemotherapy treatment given to patients who have been recently diagnosed with acute myeloid leukaemia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10454031·No longer recruiting·A clinical study in order to compare the effectiveness and safety of two different treatments in patients with newly diagnosed primary immune thrombocytopenia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14643179·Recruiting·Assessing if stopping and starting standard of care medication for later stage melanoma can reduce the body's resistance to the treatment
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12632431·Recruiting·A Phase III placebo-controlled efficacy and safety study of mocravimod as an adjunctive and maintenance treatment in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14891060·No longer recruiting·A study to investigate the pharmacokinetic profile of ALXN2050 modified release prototype formulations and immediate release reference tablet in healthy adult participants
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN23584582·No longer recruiting·Platform study Kalidescope: A Phase 1/2 Open-label Platform Study to Evaluate the Safety and Efficacy of Multiple Amivantamab-based Therapeutic Combinations in Participants with Advanced,
Unresectable Lung Cancer (LC)
ISA1 METalmark (now closed in UK): A phase I/II open-label platform study to evaluate the safety and efficacy of multiple amivantamab-based therapeutic combinations in participants with advanced, unresectable lung cancer
ISA2 Polydamas: A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab Combination Therapy in Metastatic Non-small Cell Lung Cancer
ISA3 SwalloWTail: A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14442671·No longer recruiting·A study to evaluate the drug-drug interaction potential of pralsetinib in combination with substrates of various transporters or CYP enzymes or a combined oral contraceptive in participants with advanced or metastatic solid tumors that are not responsive to standard therapies
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10010669·No longer recruiting·A study to assess the effect of tiragolumab in presence of atezolizumab and bevacizumab in participants detected with lung cancer
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for White platelet syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"White platelet syndrome"
MeSH descriptor terms unioned into the query: White platelet syndrome
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"White platelet syndrome"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T14:55:36.009Z
